OTC

Chr XX-linked

ornithine transcarbamylase

Also known as: OCTD, OTC1, OTCD, OTCase

This nuclear gene encodes a mitochondrial matrix enzyme. The encoded protein is involved in the urea cycle which functions to detoxify ammonia into urea for excretion. Mutations in this enzyme lead to ornithine transcarbamylase deficiency, which causes hyperammonemia. [provided by RefSeq, May 2022]

Primary Disease Associations & Inheritance

Ornithine transcarbamylase deficiencyMIM #311250
X-linked
UniProtOrnithine carbamoyltransferase deficiency
278
ClinVar variants
47
Pathogenic / LP
0.87
pLI score
12
Active trials
Clinical SummaryOTC
🧬
Gene-Disease Validity (ClinGen)
ornithine carbamoyltransferase deficiency · XLDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Moderately constrained gene (pLI 0.87) — some intolerance to loss-of-function variants.
📋
ClinVar Variants
47 Pathogenic / Likely Pathogenic· 120 VUS of 278 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Moderate LoF intolerance
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.41LOEUF
pLI 0.873
Z-score 3.18
OE 0.13 (0.050.41)
Moderately constrained

More LoF-intolerant than ~75% of genes

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
1.33Z-score
OE missense 0.67 (0.570.81)
89 obs / 131.9 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.13 (0.050.41)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.67 (0.570.81)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.0.97
01.21.6
LoF obs/exp: 2 / 15.5Missense obs/exp: 89 / 131.9Syn Z: 0.19

ClinVar Variant Classifications

278 submitted variants in ClinVar

Classification Summary

Pathogenic24
Likely Pathogenic23
VUS120
Likely Benign97
Benign5
Conflicting9
24
Pathogenic
23
Likely Pathogenic
120
VUS
97
Likely Benign
5
Benign
9
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
3
2
19
0
24
Likely Pathogenic
5
14
4
0
23
VUS
1
100
18
1
120
Likely Benign
0
1
60
36
97
Benign
0
0
5
0
5
Conflicting
9
Total911710637278

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

OTC · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Gene2Phenotype Curations

OTC-related ornithine transcarbamylase deficiency

definitive
Monoallelic X HemizygousLoss Of FunctionAbsent Gene Product
Dev. Disorders
G2P ↗

Gene2Phenotype curations · DECIPHER consortium patient cohort (public variants) · deciphergenomics.org

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

Ornithine transcarbamylase deficiency

MIM #311250

Molecular basis of disorder known

X-linked
📖
GeneReview available — OTC
Authoritative clinical overview · NCBI Bookshelf · Recommended first read
Open GeneReview ↗
Clinical Literature
Landmark / reviewRecent case evidence

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

COVID-19COVID

Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test

RECRUITING
NCT06744660Phase NAAptitude Medical SystemsStarted 2024-10-17
Aptitude Medical Systems Metrix COVID Test
Chronic Rhinosinusitis (Diagnosis)

Topical Probiotic Sinus Irrigations for Treating Chronic Sinusitis

RECRUITING
NCT05427695Phase PHASE2University of Illinois at ChicagoStarted 2025-02-05
Lactobacillus sakei proBio65Isotonic Saline Solution
Fertility DisordersTurner SyndromePremature Ovarian Failure

The Danish TURNER Cryopreservation Study

RECRUITING
NCT05740579Phase NAUniversity of AarhusStarted 2023-01-01
laparoscopic cryopreservation of one ovary
Intellectual Disability, MildIntellectual Disability, Mild to ModerateDevelopmental Disability

PGx Medication Safety Reviews of Persons With IDD

NOT YET RECRUITING
NCT07092852GalenusRx, Inc.Started 2025-08-01
Cheek swab for PGx testingMedication safety review
OTC Deficiency

Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency

ACTIVE NOT RECRUITING
NCT05345171Phase PHASE3Ultragenyx Pharmaceutical IncStarted 2022-10-18
DTX301PlaceboOral Corticosteroids
Microbial ColonizationEye DiseasesOphthalmopathy

Assessment of the Ocular Microbiome in Health and Disease

RECRUITING
NCT05414994Vanderbilt University Medical CenterStarted 2023-09-07
Eye swab
Ornithine Transcarbamylase (OTC) Deficiency

Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency

ACTIVE NOT RECRUITING
NCT03636438Ultragenyx Pharmaceutical IncStarted 2018-08-30
No Intervention
Schizophrenia and Related DisordersMitochondrial AlterationCognitive Impairment

MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction

RECRUITING
NCT06191965Phase PHASE2, PHASE3Mclean HospitalStarted 2024-06-01
MitoQPlacebo
Alcohol Drinking

Nicotinic Receptor Genetic Variation and Alcohol Reward

RECRUITING
NCT03294460Phase PHASE1National Institute on Alcohol Abuse and Alcoholism (NIAAA)Started 2019-06-10
Alcohol (Oral)Alcohol (IV)Alcohol (Ethanol)
COVID -19Influenza AInfluenza B

Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings

NOT YET RECRUITING
NCT07217639Phase NAAptitude Medical SystemsStarted 2025-11-01
Aptitude Medical Systems Respiratory Panel Test
Persistent Pulmonary Hypertension of the Newborn

PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn

RECRUITING
NCT00710177Medical College of WisconsinStarted 2006-01
Ornithine Transcarbamylase DeficiencyOrnithine Transcarbamylase Deficiency DiseaseOrnithine Carbamoyltransferase Deficiency (Disorder)

An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency

RECRUITING
NCT06255782Phase PHASE1, PHASE2iECURE, Inc.Started 2024-04-08
ECUR-506